Back to search results

Investigating IVIM DWI for Colorectal Cancer Liver Metastases Treatment Response

This study is looking at a new type of imaging scan called Intravoxel Incoherent Motion Diffusion Weighted Imaging (IVIM DWI) to see how well it can measure the response of colorectal cancer that has spread to the liver (liver metastases) to chemotherapy. You might be able to join if you are an adult with colorectal cancer that has spread to your liver and can be removed by surgery, and you are about to start chemotherapy with medicines like FOLFOX, FOLFIRI, or FOLFOXIRI, possibly with a biologic agent. The main goal is to see if this scan can detect differences in how the cancer responds to treatment before and after chemotherapy. The study plans to enroll 70 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific procedure (the IVIM DWI scan). It aims to enroll 70 participants.
What's involved
You would undergo an IVIM DWI scan during a standard MRI within 30 days before starting chemotherapy and again after 4-6 cycles of chemotherapy.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures changes up to 3 or 5 months, with each cycle lasting 28 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04796818

An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response

Recruiting
NAAges 18+InterventionalDiagnostic
M.D. Anderson Cancer Center
~70 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:Diffusion Weighted Imaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Absolute change in the true diffusion coefficient (D)
Measured over Up to 3 months or 5 months (each cycle is 28 days)

Conditions

Metastatic Colorectal Carcinoma
Metastatic Malignant Neoplasm in the Liver
Resectable Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8
Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8

Explore related trials

Colorectal Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Priya R Bhosale · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Priya R Bhosale
[email protected]
713-792-0221
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with treatment-naive resectable CLM, who will start chemotherapy with oxaliplatin with fluorouracil (5-FU)/leucovorin (FOLFOX), irinotecan with 5-FU/leucovorin (FOLFIRI), or a combination, such as fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), with or without a biologic agent
Patients with at least 1 colorectal liver metastasis measuring at least 1 cm
Patients with anticipated follow-up before and after surgery at MD Anderson

Exclusion

Patients who have already received preoperative chemotherapy for the CLM or will undergo radiation therapy, ablative therapies, or other non-surgical therapies directed at the liver
Patients allergic to gadolinium
Patients with pacemakers
Greater than 400 pounds in weight

What this trial measures

  • Absolute change in the true diffusion coefficient (D)Up to 3 months or 5 months (each cycle is 28 days)

    The absolute changes of parameter D between response and nonresponse groups will be compared using a two-sample t-test.